EGFR and neoplasm: These include achieving higher MAFs, tumor mutational burden, chromosomal instability, and sensitivity in locally metastatic patients, as well as higher detection of resistance-conferring (e.g., EGFR T790M) and unique mutations in advanced cancer patients, and more driver mutations in tissue-lacking patients.